
Company Legal Name
Latest Valuation
Founded Year
Headquarters
Strand Therapeutics develops next-generation mRNA therapies engineered with proprietary genetic circuits to enable precise targeting of cancer cells and controlled immune system activation. Founded in 2017 and headquartered in Boston, the company differentiates itself through programmable mRNA technology that can sense cellular environments and respond accordingly, potentially addressing safety and efficacy limitations of current mRNA therapeutics. Strand's platform technology allows for conditional expression of therapeutic proteins only in target tissues, reducing systemic toxicity while maximizing therapeutic impact. The company continues advancing its pipeline of programmable mRNA candidates for oncology and immunology applications through preclinical and clinical development stages.

Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.

Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.


